Download PDF
Arzneimittelforschung 2012; 62(07): 319-323
DOI: 10.1055/s-0032-1311609
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Formulation and Comparative Bioavailability of 2 Ciprofloxacin Sustained Release Tablets

A. N. Zaid
1   College of Pharmacy, An-Najah National University, Nablus, Palestine
,
A. Qaddomi
2   Pharmacare Ltd. Beitunia, Ramallah, Palestine
,
S. Khammash
1   College of Pharmacy, An-Najah National University, Nablus, Palestine
› Author Affiliations
Further Information

Publication History

received 15 September 2011

accepted 21 March 2012

Publication Date:
27 April 2012 (online)

    Permissions and Reprints

Abstract

Background and the purpose of the study: The aim of this study is to formulate and evaluate the quality of ciprofloxacin (CAS number: 85721-33-1) sustained release tablet (Ciprocare®XR) 1 000 mg ciprofloxacin (test formulation) by comparing its pharmacokinetic parameters with Cipro®XR sustained release tablet (reference formulation). For this purpose ciprofloxacin SR tablets were developed using the 2-layer method. To assess the quality of the produced sustained release tablets a randomized, 2-way, crossover, bioequivalence study was performed in 24 healthy, male volunteers. The selected Middle Eastern volunteers were divided into 2 groups of 12 subjects. One group was treated with the reference formulation and the other one with the test formulation, with a cross-over after a drug washout period of 7 days. Blood samples were collected at fixed time intervals and Ciprofloxacin concentrations were determined by a validated HPLC assay method. The pharmacokinetic parameters AUC0–48, AUC0–∞, Cmax, Tmax, Ke and T1/2 were determined for both sustained release tablets and were compared statistically to evaluate the bioequivalence between the 2 formulations of ciprofloxacin, using the statistical model recommended by the FDA. The analysis of variance (ANOVA) did not show any significant difference between the 2 formulations and 90% confidence intervals (CI) fell within the acceptable range for bioequivalence. According to the obtained results it was concluded that the test and reference formulations are bioequivalent, since they exhibit comparable pharmacokinetic parameters.

Key words

formulation - ciprofloxacin - bioequivalence - sustained release tablets
 

  • References

  • 1 Bauernfeind A, Petermuller C. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol 1983; 2 (02) 111-115
    CrossrefPubMedSearch in Google Scholar
  • 2 Borner K, Lode H, Elvers A. Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother 1982; 22 (06) 949-953
    CrossrefPubMedSearch in Google Scholar
  • 3 Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984; 25 (03) 319-326
    CrossrefPubMedSearch in Google Scholar
  • 4 Goodman LJ, Fliegelman RM, Trenholme GM et al. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens. Antimicrob Agents Chemother 1984; 25 (04) 504-506
    CrossrefPubMedSearch in Google Scholar
  • 5 Van Caekenberghe DL, Pattyn SR. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother 1984; 25 (04) 518-521
    CrossrefPubMedSearch in Google Scholar
  • 6 Katzung BG. Basic & clinical pharmacology. 9th ed. New York: Lange Medical Books/McGraw Hill; 2004
    Search in Google Scholar
  • 7 CIPRO Prescriber Information Bayer Healthcare Pharmaceuticals 2009
    PubMed
  • 8 Ledergerber B, Bettex JD, Joos B et al. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother 1985; 27 (03) 350-352
    CrossrefPubMedSearch in Google Scholar
  • 9 De Haan P, Lerk CF. Oral controlled release dosage forms. A review. Pharm Weekbl Sci 1984; 6 (02) 57-67
    CrossrefPubMedSearch in Google Scholar
  • 10 Stepensky D, Friedman M, Srour W et al. Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 2001; 71 (01) 107-115
    CrossrefPubMedSearch in Google Scholar
  • 11 Andersen Ø, Zweidorff O, Hjelde T et al. Problemer med a svelge tabletter Problems in swallowing tablets. Tidsskr Nor Lægeforen 1995; 115 (08) 947-949
    PubMedSearch in Google Scholar
  • 12 Cornish P. “Avoid the crush”: hazards of medication administration in patients with dysphagia or a feeding tube. CMAJ 2005; 172 (07) 871-872
    CrossrefPubMedSearch in Google Scholar
  • 13 Hey H, Sorensen K, Jorgensen FB et al. Kapslers og tabletters passagetid gennem esophagus [The transient time for capsules and tablets through the esophagus]. Ugeskr Laeger 1983; 145: 2432-2435
    PubMedSearch in Google Scholar
  • 14 Karakan Y, Akpinar A, Yildiz H et al. A case of ciprofloxacin tablet aspiration. Tuberk Toraks 2010; 58 (01) 97-99
    PubMedSearch in Google Scholar
  • 15 Overgaard AB, Hojsted J, Hansen R et al. Patients’ evaluation of shape, size and colour of solid dosage forms. Pharm World Sci 2001; 23 (05) 185-188
    CrossrefPubMedSearch in Google Scholar
  • 16 Wamberg T. Skal detvaer at slug tableter? [Does it have to be difficult swallowing tablets?]. Farmaceutisk tidende 1988; 42: 686-690
    PubMedSearch in Google Scholar
  • 17 Aulton ME. Pharmaceutics: the design and manufacture of medicines. 3rd ed. Edinburgh; New York: Churchill Livingstone; 2007
    Search in Google Scholar
  • 18 Shah VP, Midha KK, Dighe S et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16 (04) 249-255
    CrossrefPubMedSearch in Google Scholar
  • 19 FDA FDA-recommended dissolution method for ciprofloxacin extended release tablets. Available from http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm
    PubMed
  • 20 EMEA guidance: Note for guidance on the investigation of bioavailability and bioequivalence (CPMP/EWP/QWP/1401/98) 2001
    PubMed
  • 21 FDA guidance. Guidance for industry: Statistical approaches to establishing bioequivalence. 2001
    PubMedSearch in Google Scholar
  • 22 Borner K, Lode H, Hoffken G et al. Liquid chromatographic determination of ciprofloxacin and some metabolites in human body fluids. J Clin Chem Clin Biochem 1986; 24 (05) 325-331
    PubMedSearch in Google Scholar
  • 23 Chan CY, Lam AW, French GL. Rapid HPLC assay of fluoroquinolones in clinical specimens. J Antimicrob Chemother 1989; 23 (04) 597-604
    CrossrefPubMedSearch in Google Scholar
  • 24 el-Yazigi A, al-Rawithy S. A direct liquid chromatographic quantitation of ciprofloxacin in microsamples of plasma with fluorometric detection. Ther Drug Monit 1990; 12 (04) 378-381
    CrossrefPubMedSearch in Google Scholar
  • 25 Chow S-C, Liu J-p. Design and analysis of bioavailability and bioequivalence studies. New York: M. Dekker; 1992
    Search in Google Scholar